12-11-2006, 12:53 PM
|
|
Administrator
|
|
Join Date: Nov 2006
Posts: 72
|
|
Results Reported at the American Society of Hematology Annual Meeting Affirm Impressi
A new story entry has been added:
Results Reported at the American Society of Hematology Annual Meeting Affirm Impressive Activity of Allos Therapeutics'
Quote:
|
Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced the presentation of interim results from its on-going Phase 1/2 trial of PDX (pralatrexate) in patients with relapsed or refractory non-Hodgkin's Lymphoma and Hodgkin's Disease. Owen A. O'Connor, M.D., Ph.D., Head of the Laboratory of Experimental Therapeutics for Lymphoproliferative Malignancies, Lymphoma and Development Chemotherapy Services, Memorial Sloan-Kettering Cancer Center (MSKCC), and the study's principal investigator, presented the findings in an oral presentation today at the 48th Annual Meeting of the American Society of Hematology in Orlando, FL.
|
|
Linear Mode
